Glaukos Co. (NYSE:GKOS) Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC grew its stake in shares of Glaukos Co. (NYSE:GKOS) by 44.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,601 shares of the medical instruments supplier’s stock after acquiring an additional 9,139 shares during the period. Intech Investment Management LLC owned about 0.05% of Glaukos worth $4,438,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in GKOS. Victory Capital Management Inc. lifted its position in shares of Glaukos by 421.8% in the 3rd quarter. Victory Capital Management Inc. now owns 79,211 shares of the medical instruments supplier’s stock worth $10,320,000 after buying an additional 64,031 shares during the last quarter. KBC Group NV lifted its position in shares of Glaukos by 16.2% in the 3rd quarter. KBC Group NV now owns 1,445 shares of the medical instruments supplier’s stock worth $188,000 after buying an additional 201 shares during the last quarter. Natixis Advisors LLC lifted its position in shares of Glaukos by 1.2% in the 3rd quarter. Natixis Advisors LLC now owns 37,738 shares of the medical instruments supplier’s stock worth $4,917,000 after buying an additional 441 shares during the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Glaukos by 3.2% in the 3rd quarter. Thrivent Financial for Lutherans now owns 43,152 shares of the medical instruments supplier’s stock worth $5,622,000 after buying an additional 1,339 shares during the last quarter. Finally, LMR Partners LLP lifted its position in shares of Glaukos by 12.3% in the 3rd quarter. LMR Partners LLP now owns 36,986 shares of the medical instruments supplier’s stock worth $4,819,000 after buying an additional 4,059 shares during the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds.

Glaukos Stock Performance

Glaukos stock opened at $100.36 on Wednesday. The firm’s 50 day simple moving average is $138.69 and its 200-day simple moving average is $137.25. The company has a market cap of $5.68 billion, a P/E ratio of -34.97 and a beta of 0.99. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos Co. has a fifty-two week low of $85.23 and a fifty-two week high of $163.71.

Glaukos (NYSE:GKOS) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.02). The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. As a group, equities research analysts predict that Glaukos Co. will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

GKOS has been the topic of a number of recent research reports. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $140.00 to $200.00 in a research report on Wednesday, February 19th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price objective (up from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Needham & Company LLC lifted their price objective on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Morgan Stanley downgraded shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a research report on Monday, December 2nd. Finally, Stifel Nicolaus boosted their price target on shares of Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, December 31st. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and an average target price of $163.25.

Insider Activity at Glaukos

In related news, COO Joseph E. Gilliam sold 3,328 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $149.85, for a total transaction of $498,700.80. Following the transaction, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at approximately $15,310,024.65. The trade was a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,744 shares of company stock valued at $2,504,131. Corporate insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.